In vivo visible light-triggered drug release from an implanted depot

Carling, Carl-Johan; Viger, Mathieu L.; Huu, Viet Anh Nguyen; Garcia, Arnold; Almutairi, Adah

doi:10.1039/c4sc02651a

Cited by 64 publications

(52 citation statements)

References 43 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…It will be an important move forward to have universal nanomedicine platforms that address the main disease together with the medical complications associated with the same. Also, with the introduction of novel stimuli-responsive nanomaterials [187], we envision similar products in the market that will release the encapsulated drugs on demand. Another area that we feel the field might also benefit from is the design of particles that enable a dynamic control over their biodegradation after being introduced into the human body.…”

Section: Discussionmentioning

confidence: 99%

Evolution and clinical translation of drug delivery nanomaterials

et al. 2017

View full text Add to dashboard Cite

With the advent of technology, the role of nanomaterials in medicine has grown exponentially in the last few decades. The main advantage of such materials has been exploited in drug delivery applications, due to their effective targeting that in turn reduces systemic toxicity compared to the conventional routes of drug administration. Even though these materials offer broad flexibility based on targeting tissue, disease, and drug payload, the demand for more effective yet highly biocompatible nanomaterial-based drugs is increasing. While therapeutically improved and safe materials have been introduced in nanomedicine platforms, issues related to their degradation rates and bio-distribution still exist, thus making their successful translation for human use very challenging. Researchers are constantly improving upon novel nanomaterials that are safer and more effective not only as therapeutic agents but as diagnostic tools as well, making the research in the field of nanomedicine ever more fascinating. In this review stress has been made on the evolution of nanomaterials that have been approved for clinical applications by the United States Food and Drug Administration Agency (FDA).

show abstract

Section: Discussionmentioning

confidence: 99%

Evolution and clinical translation of drug delivery nanomaterials

et al. 2017

View full text Add to dashboard Cite

show abstract

“…The organic layer was washed extensively with water and evaporated under reduced pressure to give a white solid (63 mg, 100%). 1 H NMR (600 MHz, DMSO-d 6 13 …”

Section: ■ Experimental Sectionmentioning

confidence: 99%

“…Similar treatment gave an additional 365 mg, for an overall yield of 1.23 g (65%), Alternatively, the product was recovered from the DCM phase without ether precipitation (85% yield, with residual DIEA). 1 H NMR (600 MHz, DMSO-d 6 Synthesis of 6. After dissolution of 5 (57 mg, 0.1 mmol) in EtOAc (1.5 mL), a solution of K 2 CO 3 (138.1 mg, 1 mmol) in water (1.5 mL) was added, and the resulting mixture was stirred vigorously at 0°C.…”

Section: ■ Experimental Sectionmentioning

confidence: 99%

Short Soluble Coumarin Crosslinkers for Light-Controlled Release of Cells and Proteins from Hydrogels

Lux¹,

Lux²,

Collet³

et al. 2015

Biomacromolecules

Self Cite

View full text Add to dashboard Cite

Materials that degrade or dissociate in response to low power light promise to enable on-demand, precisely localized delivery of drugs or bioactive molecules in living systems. Such applications remain elusive because few materials respond to wavelengths that appreciably penetrate tissues. The photocage bromohydroxycoumarin (Bhc) is efficiently cleaved upon low-power ultraviolet (UV) and near-infrared (NIR) irradiation through one- or two-photon excitation, respectively. We have designed and synthesized a short Bhc-bearing crosslinker to create light-degradable hydrogels and nanogels. Our crosslinker breaks by intramolecular cyclization in a manner inspired by the naturally occurring ornithine lactamization, in response to UV and NIR light, enabling rapid degradation of polyacrylamide gels and release of small hydrophilic payloads such as an ∼10 nm model protein and murine mesenchymal stem cells, with no background leakage.

show abstract

“…They have been explored for drug delivery through a variety of administration routes (such as oral, injected, inhaled, and implanted) and also as stents in tissue engineering [7][8][9][10][11]. Two trends are obvious with this type of biomaterials.…”

Section: Introductionmentioning

confidence: 99%

Nanosized sustained-release drug depots fabricated using modified tri-axial electrospinning

Yang

et al. 2017

Acta Biomaterialia

124

View full text Add to dashboard Cite

Nanosized sustainedrelease drug depots fabricated using modified tri-axial electrospinning, Acta Biomaterialia (2017), doi: http:// dx.doi.org/10. 1016/j.actbio.2017.01.069 This is a PDF file of an unedited manuscript that has been accepted for publication. As a service to our customers we are providing this early version of the manuscript. The manuscript will undergo copyediting, typesetting, and review of the resulting proof before it is published in its final form. Please note that during the production process errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.Nanosized sustained-release drug depots fabricated using modified tri-axial electrospinning Abstract:Nanoscale drug depots, comprising a drug reservoir surrounded by a carrier membrane, are much sought after in contemporary pharmaceutical research. Using cellulose acetate (CA) as a filament-forming polymeric matrix and ferulic acid (FA) as a model drug, nanoscale drug depots in the form of core-shell fibers were designed and fabricated using a modified tri-axial electrospinning process. This employed a solvent mixture as the outer working fluid, as a result of which a robust and continuous preparation process could be achieved. The fiber-based depots had a linear morphology, smooth surfaces, and an average diameter of 0.62 ± 0.07 µm. Electron microscopy data showed them to have clear core-shell structures, with the FA encapsulated inside a CA shell. X-ray diffraction and IR spectroscopy results verified that FA was present in the crystalline physical form. In vitro dissolution tests revealed that the fibers were able to provide close to zero-order release over 36 h, with no initial burst release and minimal tailing-off. The release properties of the depot systems were much improved over monolithic CA/FA fibers, which exhibited a significant burst release and also considerable tailing-off at the end of the release experiment. Here we thus demonstrate the concept of using modified tri-axial electrospinning to design and develop new types of heterogeneous nanoscale biomaterials.

show abstract

In vivo visible light-triggered drug release from an implanted depot

Cited by 64 publications

References 43 publications

Evolution and clinical translation of drug delivery nanomaterials

Evolution and clinical translation of drug delivery nanomaterials

Short Soluble Coumarin Crosslinkers for Light-Controlled Release of Cells and Proteins from Hydrogels

Nanosized sustained-release drug depots fabricated using modified tri-axial electrospinning

Contact Info

Product

Resources

About